secwatch.observer — SEC 8-K summary
======================================

Issuer:     SIGA TECHNOLOGIES INC (SIGA)
CIK:        0001010086
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001140361-22-007678
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SIGA reports 2021 revenue $133.7M, net income $69.5M; EPS $0.91; EMA approves TPOXX
--------------------------------------------------------------------------------

- FY2021 total revenues $133.7M; net income $69.5M ($0.91 diluted EPS) vs $56.3M ($0.71) in FY2020.
- Q4 2021 revenues $115.4M ($73.2M net income, $0.98 EPS) driven by $113M U.S. delivery of oral TPOXX.
- International product sales $13M in 2021, up from $2M; EMA approved oral TPOXX in Jan 2022, Health Canada in Dec 2021.
- SIGA repurchased ~3.8M shares for $26M in 2021 (~5% of shares outstanding); collaboration with Bioarchitech on immunotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1010086/000114036122007678/0001140361-22-007678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1010086/000114036122007678/brhc10034763_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-007678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer